Patients with higher body mass index treated with direct/novel oral anticoagulants (DOAC/NOAC) for atrial fibrillation experience worse clinical outcomes
M Lucijanic, I Jurin, H Jurin, T Lucijanic… - International journal of …, 2020 - Elsevier
Introduction Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists
about their efficacy in a population of obese/overweight patients. Patients and methods We …
about their efficacy in a population of obese/overweight patients. Patients and methods We …
Patients with higher body mass index treated with direct/novel oral anticoagulants (DOAC/NOAC) for atrial fibrillation experience worse clinical outcomes
M Lucijanić, I Jurin, H Jurin, T Lucijanić… - International …, 2020 - repozitorij.mef.unizg.hr
Abstract (english) Introduction: Due to fixed dosing of direct oral anticoagulants (DOACs),
uncertainty exists about their efficacy in a population of obese/overweight patients …
uncertainty exists about their efficacy in a population of obese/overweight patients …
Patients with higher body mass index treated with direct/novel oral anticoagulants (DOAC/NOAC) for atrial fibrillation experience worse clinical outcomes
M Lucijanić, I Jurin, H Jurin, T Lucijanić… - International Journal of …, 2020 - dabar.srce.hr
Abstract (english) Introduction: Due to fixed dosing of direct oral anticoagulants (DOACs),
uncertainty exists about their efficacy in a population of obese/overweight patients …
uncertainty exists about their efficacy in a population of obese/overweight patients …
Patients with higher body mass index treated with direct/novel oral anticoagulants (DOAC/NOAC) for atrial fibrillation experience worse clinical outcomes.
M Lucijanic, I Jurin, H Jurin, T Lucijanic… - … Journal of Cardiology, 2019 - europepmc.org
Results Patients with higher BMI receiving DOACs were more likely to experience
stroke/systemic embolism sooner (P= 0.043), experience major bleeding sooner (P< 0.001) …
stroke/systemic embolism sooner (P= 0.043), experience major bleeding sooner (P< 0.001) …
Patients with higher body mass index treated with direct/novel oral anticoagulants (DOAC/NOAC) for atrial fibrillation experience worse clinical outcomes
M Lucijanic, I Jurin, H Jurin… - International …, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists
about their efficacy in a population of obese/overweight patients. Patients and methods We …
about their efficacy in a population of obese/overweight patients. Patients and methods We …
Patients with higher body mass index treated with direct/novel oral anticoagulants (DOAC/NOAC) for atrial fibrillation experience worse clinical outcomes
M Lucijanic, I Jurin, H Jurin… - International …, 2020 - internationaljournalofcardiology.com
Introduction Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists
about their efficacy in a population of obese/overweight patients. Patients and methods We …
about their efficacy in a population of obese/overweight patients. Patients and methods We …
Patients with higher body mass index treated with direct/novel oral anticoagulants (DOAC/NOAC) for atrial fibrillation experience worse clinical outcomes
M Lucijanic, I Jurin, H Jurin, T Lucijanic… - International journal of …, 2020 - croris.hr
Sažetak INTRODUCTION: Due to fixed dosing of direct oral anticoagulants (DOACs),
uncertainty exists about their efficacy in a population of obese/overweight patients …
uncertainty exists about their efficacy in a population of obese/overweight patients …
Patients with higher body mass index treated with direct/novel oral anticoagulants (DOAC/NOAC) for atrial fibrillation experience worse clinical outcomes
M Lucijanić, I Jurin, H Jurin, T Lucijanić… - International Journal …, 2020 - repozitorij.unizg.hr
Obesity, simply defined as an excess of body weight for height, is a complex multifactorial
disease affecting one third of world's population [1]. It can be classified as class I (body mass …
disease affecting one third of world's population [1]. It can be classified as class I (body mass …
Patients with higher body mass index treated with direct/novel oral anticoagulants (DOAC/NOAC) for atrial fibrillation experience worse clinical outcomes.
M Lucijanic, I Jurin, H Jurin, T Lucijanic, B Starcevic… - 2020 - cabidigitallibrary.org
Introduction: Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists
about their efficacy in a population of obese/overweight patients. Patients and methods: We …
about their efficacy in a population of obese/overweight patients. Patients and methods: We …
[PDF][PDF] Patients with higher body mass index treated with direct/novel oral anticoagulants (DOAC/NOAC) for atrial fibrillation experience worse clinical outcomes
I Hadžibegović - repozitorij.unizg.hr
Obesity, simply defined as an excess of body weight for height, is a complex multifactorial
disease affecting one third of world's population [1]. It can be classified as class I (body mass …
disease affecting one third of world's population [1]. It can be classified as class I (body mass …